Clinical Trial

Study of EV for Recurrent Endometrial Carcinoma

Study acronym: EV-4-EC
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is testing a drug called enfortumab vedotin in up to 12 patients with advanced endometrial (uterine) cancer that has worsened after previous treatments, including immunotherapy. The goal is to see how well the drug works and how safe it is. Patients will be treated for up to one year and followed over time to monitor their health and response to the treatment.
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-14
Trial Details
NCT Number NCT07139977
Lead Sponsor William Bradley
Collaborators: Astellas Pharma Inc
Conditions Endometrial Cancer
Enrollment 12 participants
Start Date 2026-07-10
Primary Completion 2027-11-30 (estimated)
Study Completion 2028-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-13